Aspen Aerogels, Inc. (NYSE:ASPN) Given Average Rating of “Hold” by Analysts

Aspen Aerogels, Inc. (NYSE:ASPN) has been assigned an average rating of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $5.9375.

ASPN has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aspen Aerogels in a report on Wednesday, June 24th. B. Riley Financial reaffirmed a “buy” rating on shares of Aspen Aerogels in a research report on Friday, August 7th. Wall Street Zen lowered shares of Aspen Aerogels from a “hold” rating to a “sell” rating in a report on Saturday. Roth Capital reissued a “buy” rating and set a $7.75 price objective on shares of Aspen Aerogels in a research note on Friday, August 7th. Finally, Barclays increased their target price on Aspen Aerogels from $4.00 to $5.00 and gave the stock an “underweight” rating in a research report on Tuesday, August 11th.

Aspen Aerogels Price Performance

ASPN stock opened at $5.83 on Tuesday. The stock has a market capitalization of $483.83 million, a price-to-earnings ratio of -3.81 and a beta of 2.99. The company has a quick ratio of 2.24, a current ratio of 2.52 and a debt-to-equity ratio of 0.36. Aspen Aerogels has a 52-week low of $2.30 and a 52-week high of $9.35. The stock’s fifty day simple moving average is $5.52 and its 200-day simple moving average is $4.53.

Aspen Aerogels (NYSE:ASPN) last released its earnings results on Thursday, August 6th. The construction company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. Aspen Aerogels had a negative return on equity of 31.12% and a negative net margin of 62.45%.The firm had revenue of $49.85 million for the quarter, compared to the consensus estimate of $42.42 million. Aspen Aerogels has set its Q3 2026 guidance at -0.110–0.070 EPS. Equities research analysts expect that Aspen Aerogels will post -0.69 EPS for the current year.

Institutional Trading of Aspen Aerogels

Institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new position in Aspen Aerogels in the second quarter valued at approximately $33,457,000. Oaktop Capital Management II L.P. acquired a new stake in shares of Aspen Aerogels in the second quarter worth $32,769,000. George Kaiser Family Foundation purchased a new position in shares of Aspen Aerogels in the 2nd quarter valued at $20,081,000. Invesco Ltd. lifted its holdings in shares of Aspen Aerogels by 237.9% during the 4th quarter. Invesco Ltd. now owns 4,129,934 shares of the construction company’s stock valued at $11,688,000 after acquiring an additional 2,907,558 shares in the last quarter. Finally, Rice Hall James & Associates LLC purchased a new stake in Aspen Aerogels during the 2nd quarter worth $10,368,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.

The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.